Abstract: The invention relates to the triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives of general formula (I): Wherein X, A, R1 and R2 are as defined herein. The invention further relates to preparation methods and therapeutic use thereof.

Abstract: The invention relates to therapeutic use of compounds of general formula (I): in which X1, X2, X3, X4, X5, Z1, Z2, Z3, Z4 and Z5, R, Y and n are as defined herein.

Abstract: The invention relates to therapeutic use of compounds of general formula (I): in which X1, X2, X3, X4, X5, Z1, Z2, Z3, Z4 and Z5, R, Y and n are as defined herein.

Abstract: The invention concerns tricyclic N-heteroarylcarboxamide derivatives containing a benzimidazole unit of general formula (I): Wherein A, P, Y, R1, R2 and R3 are as defined herein. The invention also concerns a method of preparing the compounds and their therapeutic use.

Abstract: The invention relates to therapeutic use of compounds of general formula (I): in which X1, X2, X3, X4, X5, Z1, Z2, Z3, Z4 and Z5, R, Y and n are as defined herein.

Abstract: The invention relates to compounds of general formula (I): in which X1, X2, X3, X4, X5, Z1, Z2, Z3, Z4 and Z5, R, Y and n are as defined herein. Also disclosed and claimed are the preparative methods and application of said compounds in therapeutics.

Abstract: The invention relates to compounds of general formula (I): in which X1, X2, X3, X4, X5, Z1, Z2, Z3, Z4 and Z5, R, Y and n are as defined herein. Also disclosed and claimed are the preparative methods and application of said compounds in therapeutics.

Abstract: The invention relates to 2,5-diazabicyclo[2.2.1]heptane derivatives, to pharmaceutical compositions containing them, and to methods for the treatment or prevention of disorders associated with a dysfunction of the nicotinic receptors utilizing them.

Abstract: The invention relates to 1,4-diazabicyclo[3.2.2]nonane derivatives, to pharmaceutical compositions containing them, and to methods for the treatment or prevention of disorders associated with a dysfunction of the nicotinic receptors utilizing them.

Abstract: The invention concerns the use of mizolastine and the pharmaceutically acceptable salts thereof for making a medicine for treating inflammatory diseases or inflammatory constituents of some other diseases related to the 5-lipoxygenase route.

Abstract: A compound of formula (I): ##STR1## in which R.sub.1 represents a hydrogen atom or a straight or branched (C.sub.1 -C.sub.4)alkyl group; andA represents a 5,6-dihydro-4H-imidazo[4,5,1-ij]quinol-2-yl group, a 4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl group, a 4-methyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl group, a 4-phenyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl group, a 4-phenylmethyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl group, a 5-methyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl group, a 5,6-dihydro-4H-imidazo[1,5,4-de]quinoxalin-2-yl group, a 6-oxo-5,6-dihydro-4H-imidazo[4,5,1-ij]quinol-2-yl group, or a 5-methyl-4,5,6,7-tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2-yl group which may be unsubstituted or substituted in the 6-position by a phenylmethyl group;or an addition salt thereof with a pharmaceutically acceptable acid.